1. A 44-year-old man who received a kidney transplant 18 months ago is maintained on tacrolimus for immunosuppression. He presents to clinic with 3 days of productive cough, fever, and a chest X-ray showing a right lower lobe infiltrate consistent with community-acquired pneumonia. His creatinine is at his stable post-transplant baseline of 1.6 mg/dL. The team decides to treat empirically with a macrolide to cover atypical organisms. Which of the following macrolide choices is most appropriate, and what is the primary pharmacokinetic reason?
A) Erythromycin is most appropriate because its short serum half-life of approximately 1.5 to 2 hours limits the duration of any drug interaction with tacrolimus, and the interaction can be managed with twice-weekly tacrolimus trough monitoring during the antibiotic course
B) Clarithromycin is most appropriate because its active 14-hydroxyclarithromycin metabolite provides superior coverage of Legionella pneumophila compared to azithromycin and does not inhibit the calcineurin inhibitor binding site on FKBP12 that tacrolimus requires for immunosuppressive activity
C) Any of the three major macrolides is equally acceptable because tacrolimus dose can be empirically reduced by 50% at the time the macrolide is started and restored after completion, a strategy validated in transplant pharmacology guidelines for macrolide co-administration
D) Azithromycin is most appropriate because it produces negligible CYP3A4 inhibition and does not significantly inhibit P-glycoprotein at clinical doses; erythromycin and clarithromycin are both potent mechanism-based CYP3A4 inhibitors that would substantially elevate tacrolimus concentrations, risking calcineurin inhibitor nephrotoxicity in a patient with already compromised renal function
E) Clarithromycin is most appropriate because transplant patients have upregulated hepatic CYP3A4 due to chronic tacrolimus use, and clarithromycin's CYP3A4 inhibition normalizes enzyme activity to levels seen in non-immunosuppressed patients, paradoxically reducing the interaction risk compared to the non-transplant population
ANSWER: D
Rationale:
Tacrolimus is a calcineurin inhibitor with a narrow therapeutic index that undergoes extensive CYP3A4-mediated hepatic and intestinal metabolism. Erythromycin and clarithromycin are both potent mechanism-based CYP3A4 inhibitors — each generates a nitrosoalkane intermediate that irreversibly inactivates CYP3A4, requiring de novo enzyme synthesis for recovery. Co-administration of either agent with tacrolimus substantially reduces tacrolimus clearance, elevating trough and peak concentrations to levels associated with calcineurin inhibitor nephrotoxicity, neurotoxicity, and other toxicity manifestations. In this patient, whose baseline creatinine of 1.6 mg/dL already reflects reduced renal reserve from his transplant, supratherapeutic tacrolimus concentrations carry a meaningful risk of further nephrotoxicity or acute rejection if concentrations later fall. Azithromycin does not generate the nitrosoalkane CYP3A4 inhibitory intermediate and produces negligible CYP3A4 inhibition at clinical doses, making it the correct macrolide choice in transplant recipients on calcineurin inhibitors. Its atypical organism coverage — Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila — is fully adequate for empiric community-acquired pneumonia.
Option A: Option A is incorrect because erythromycin's mechanism-based CYP3A4 inhibition is irreversible; recovery depends on new enzyme synthesis over days, not on drug plasma half-life, and twice-weekly tacrolimus monitoring does not prevent the tacrolimus concentration rise that occurs in the first days of erythromycin co-administration.
Option B: Option B is incorrect because clarithromycin is a significant CYP3A4 inhibitor through the same nitrosoalkane mechanism as erythromycin; its 14-hydroxy metabolite does not protect against tacrolimus interaction, and clarithromycin does not inhibit the FKBP12 binding site — tacrolimus binds FKBP12 in a pharmacodynamic interaction unrelated to its metabolism.
Option C: Option C is incorrect because empirically reducing tacrolimus by 50% is not a validated or safe strategy for managing this interaction; the degree of CYP3A4 inhibition varies and a fixed 50% reduction could produce supratherapeutic or subtherapeutic tacrolimus levels; azithromycin avoidance of the interaction is the pharmacologically sound approach.
Option E: Option E is incorrect because chronic tacrolimus use does not upregulate hepatic CYP3A4; tacrolimus is a CYP3A4 substrate, not an inducer, and the premise that clarithromycin CYP3A4 inhibition normalizes enzyme activity in transplant patients is pharmacologically unfounded.
2. A 58-year-old man with hyperlipidemia on long-term simvastatin 40 mg daily was prescribed clarithromycin 500 mg twice daily as part of a Helicobacter pylori eradication regimen 10 days ago. He now presents with diffuse muscle pain, proximal muscle weakness, and dark urine. Laboratory results show creatine kinase (CK) 18,400 U/L, creatinine 2.1 mg/dL (baseline 0.9 mg/dL), and myoglobinuria on urinalysis. Which of the following best explains the mechanism responsible for this presentation and identifies the correct immediate management step?
A) Clarithromycin directly inhibits mitochondrial protein synthesis in skeletal muscle by binding to mitochondrial 50S ribosomes, producing a toxic myopathy that is additive with simvastatin's intrinsic myotoxicity; immediate management requires stopping clarithromycin while continuing simvastatin at a reduced dose of 10 mg daily
B) Clarithromycin inhibited CYP3A4-mediated metabolism of simvastatin, substantially elevating simvastatin plasma concentrations to levels that caused rhabdomyolysis through impaired mitochondrial coenzyme Q10 synthesis in skeletal muscle; both simvastatin and clarithromycin should be stopped immediately, and aggressive intravenous fluid resuscitation initiated to prevent myoglobin-induced acute kidney injury
C) Clarithromycin inhibited OATP1B1-mediated hepatic uptake of simvastatin, reducing simvastatin delivery to the liver and causing systemic redistribution of simvastatin to skeletal muscle where it caused direct sarcolemmal toxicity; management requires stopping simvastatin and switching to rosuvastatin, which can be continued alongside clarithromycin because it is not transported by OATP1B1
D) Simvastatin inhibited clarithromycin metabolism by competing for CYP3A4 binding, elevating clarithromycin plasma concentrations to levels that directly damaged skeletal muscle by blocking the motilin receptors responsible for muscle mitochondrial fuel delivery; both drugs should be stopped and dantrolene administered to reverse the motilin receptor blockade
E) Clarithromycin's QTc-prolonging effect caused repetitive subclinical ventricular arrhythmias that reduced skeletal muscle perfusion over 10 days, producing ischemic rhabdomyolysis; simvastatin's independent HMG-CoA reductase inhibition in cardiac muscle amplified the arrhythmia severity; management requires immediate cardiac monitoring and stopping clarithromycin only
ANSWER: B
Rationale:
This presentation is classic rhabdomyolysis — markedly elevated CK, acute kidney injury (creatinine rising from 0.9 to 2.1 mg/dL), and myoglobinuria — precipitated by a pharmacokinetic drug interaction. Clarithromycin is a potent mechanism-based CYP3A4 inhibitor that irreversibly inactivates CYP3A4 by generating a nitrosoalkane intermediate. Simvastatin is among the statins most dependent on CYP3A4 for first-pass and systemic metabolism; when CYP3A4 is inhibited, simvastatin plasma concentrations rise substantially to levels associated with skeletal muscle toxicity. The proposed mechanism of statin myopathy involves impaired mitochondrial function in skeletal muscle, including effects on coenzyme Q10 (ubiquinone) synthesis, which depends on the mevalonate pathway that HMG-CoA reductase inhibitors block at very high exposures. Immediate management requires stopping both drugs: simvastatin (to remove the myotoxic driver) and clarithromycin (to allow CYP3A4 activity to recover as new enzyme is synthesized). Aggressive IV fluid resuscitation is essential to maintain urine output and flush myoglobin from the renal tubules before it causes obstructive acute tubular necrosis — a potentially irreversible complication.
Option A: Option A is incorrect because clarithromycin does not inhibit mitochondrial protein synthesis in skeletal muscle through mitochondrial ribosome binding; that would be an antimicrobial mechanism, and the presentation is caused by CYP3A4 inhibition elevating simvastatin levels, not direct clarithromycin myotoxicity; simvastatin should be stopped, not reduced.
Option C: Option C is incorrect because the primary mechanism of the clarithromycin-simvastatin interaction is CYP3A4 inhibition, not OATP1B1 transporter inhibition; OATP1B1 inhibition is the relevant mechanism for interactions between statins and gemfibrozil or cyclosporine, and switching to rosuvastatin does not address the acute rhabdomyolysis already present.
Option D: Option D is incorrect because simvastatin does not inhibit clarithromycin metabolism in a clinically significant way; the interaction is unidirectional (clarithromycin inhibits simvastatin metabolism) and motilin receptor blockade has no role in skeletal muscle fuel delivery or rhabdomyolysis.
Option E: Option E is incorrect because QTc prolongation producing ischemic rhabdomyolysis through reduced skeletal muscle perfusion is not the mechanism of this presentation; the pharmacokinetic CYP3A4-mediated simvastatin accumulation is the established mechanism, and dantrolene and cardiac monitoring without stopping both causative drugs are insufficient responses.
3. A 36-year-old man with HIV infection presents for follow-up. He is not currently on antiretroviral therapy. His CD4 count is 38 cells per microliter and he has no current symptoms of opportunistic infection. His physician initiates primary prophylaxis against Mycobacterium avium complex (MAC). A pharmacy student on rotation asks why the prescribed regimen of azithromycin 1200 mg once weekly is adequate for prophylaxis against an organism that would require daily combination therapy to treat. Which of the following best explains the pharmacokinetic basis for once-weekly dosing adequacy in the prophylactic setting?
A) Azithromycin 1200 mg produces bactericidal serum concentrations against MAC organisms for exactly 7 days after administration; the drug's long plasma half-life of 168 hours means trough serum concentrations remain above the MAC minimum inhibitory concentration at the moment the next weekly dose is given
B) Azithromycin undergoes weekly biliary excretion cycles synchronized with the normal gallbladder contraction rhythm; the 1200 mg weekly dose matches this excretion cycle, releasing drug from bile into the intestinal lumen on a weekly schedule that maintains continuous intestinal mucosal concentrations against MAC colonization before systemic dissemination
C) Azithromycin 1200 mg weekly is effective because MAC organisms have a doubling time of exactly 7 days; the weekly dose eradicates each generation of MAC before it can replicate, and since no MAC generation survives to produce drug-resistant progeny, resistance does not emerge during prophylaxis
D) Azithromycin at 1200 mg weekly achieves serum concentrations that activate host complement pathways against MAC organisms; once activated, complement-mediated opsonization persists for 7 days until the next dose, providing immunological rather than direct antibacterial MAC prophylaxis
E) Azithromycin accumulates extensively in phagocytic cells including alveolar macrophages and monocytes — the compartment where MAC organisms initially establish infection — achieving tissue concentrations far exceeding simultaneous serum levels; the tissue half-life of approximately 68 hours in these cells sustains intracellular drug concentrations at prophylactically effective levels throughout the dosing interval between weekly doses
ANSWER: E
Rationale:
Azithromycin's suitability for once-weekly MAC prophylaxis is a direct consequence of its tissue pharmacokinetics. As an azalide, azithromycin is avidly taken up by phagocytic cells — alveolar macrophages, monocytes, and neutrophils — achieving intracellular concentrations 10 to 100 times higher than concurrent serum levels. The tissue half-life within these cells is approximately 68 hours, far exceeding the serum half-life. Because MAC organisms are intracellular pathogens that establish infection within macrophages, the relevant drug concentration is the intracellular concentration in phagocytes, not the serum concentration. After a 1200 mg weekly dose, azithromycin concentrations in macrophages remain at prophylactically effective levels throughout the 7-day dosing interval, despite serum levels falling to low values between doses. This pharmacokinetic profile — extraordinary phagocytic cell accumulation combined with a long tissue half-life — makes once-weekly dosing not only feasible but rational for prophylaxis in the macrophage compartment where MAC resides.
Option A: Option A is incorrect because azithromycin's relevant half-life for MAC prophylaxis is the tissue (intracellular) half-life, not a 168-hour plasma half-life; azithromycin serum concentrations fall substantially between weekly doses and do not maintain concentrations above the MAC MIC in plasma throughout the dosing interval — the prophylactic effect depends on intracellular, not serum, drug concentrations.
Option B: Option B is incorrect because azithromycin excretion does not occur in synchronized weekly biliary cycles tied to gallbladder contraction rhythm; azithromycin is excreted primarily unchanged in bile, but this is a continuous elimination process, not a weekly pulse synchronized with prophylactic dosing.
Option C: Option C is incorrect because MAC organisms do not have a doubling time of exactly 7 days; MAC replicates slowly but not on a schedule that synchronizes with weekly dosing, and the mechanism of prophylactic efficacy is intracellular drug concentration maintenance, not generational eradication timed to replication cycles.
Option D: Option D is incorrect because azithromycin does not exert its MAC prophylactic effect through complement pathway activation; its mechanism is direct intracellular antibacterial activity within macrophages at the site of potential MAC establishment, not immunological complement-mediated opsonization.
4. A 52-year-old woman is hospitalized with a deep wound infection of her lower extremity. Wound cultures grow Staphylococcus aureus. The susceptibility report shows erythromycin resistant, clindamycin susceptible (MIC 0.25 mcg/mL). The laboratory appends a note: "D-zone test positive." The surgical team plans to treat with clindamycin based on the susceptible MIC result. Which of the following represents the correct interpretation of the complete susceptibility data and the appropriate management decision?
A) The positive D-zone test indicates inducible MLSB resistance: the organism harbors an erm methylase gene that is not expressed under standard testing conditions but can be induced in vivo by macrolide-like signals; in vivo clindamycin therapy may select for constitutive erm-expressing mutants that are fully resistant to clindamycin, causing treatment failure despite the susceptible MIC; the isolate should be treated as clindamycin-resistant and an alternative agent such as trimethoprim-sulfamethoxazole, doxycycline, or linezolid selected based on susceptibility
B) The positive D-zone test confirms that the organism's clindamycin susceptibility result is a true susceptibility, not a testing artifact; the D-zone flattening occurs because erythromycin disk proximity enhances clindamycin diffusion through the agar, producing artificially wide inhibition zones in standard testing that are corrected by the D-zone adjustment; the clindamycin MIC of 0.25 mcg/mL is reliable and clindamycin therapy should proceed
C) The positive D-zone test indicates constitutive MLSB resistance in which both macrolides and clindamycin are always expressed as resistant; the clindamycin MIC of 0.25 mcg/mL is a laboratory error caused by pipetting the wrong organism into the clindamycin well; repeat susceptibility testing should be performed before any antibiotic decision is made
D) The positive D-zone test indicates the M phenotype of macrolide resistance in which a mef efflux pump is overexpressed; the D-zone flattening occurs because erythromycin proximity upregulates mef pump activity, which begins to efflux clindamycin in the adjacent zone; clindamycin can be used safely because mef efflux of clindamycin is only transient during the induction phase and does not persist at therapeutic drug concentrations
E) The positive D-zone test result is a known false positive for organisms with erythromycin MICs above 256 mcg/mL; high-level erythromycin resistance produces non-specific inhibition zone distortion around adjacent clindamycin disks that mimics inducible MLSB resistance; the clindamycin susceptible result should be trusted and clindamycin therapy initiated
ANSWER: A
Rationale:
A positive D-zone test on a Staphylococcus aureus isolate that is erythromycin-resistant but clindamycin-susceptible by standard MIC testing indicates inducible MLSB resistance. This organism harbors an erm methylase gene whose expression is normally suppressed — producing a susceptible clindamycin MIC in standard testing where no macrolide inducer is present — but which can be induced when the organism is exposed to macrolide-like inducers in the clinical environment. The D-zone test unmasks this hidden resistance by demonstrating that subinhibitory erythromycin concentrations adjacent to the clindamycin disk induce erm expression, producing characteristic flattening of the clindamycin inhibition zone on the facing side. The critical clinical implication is that within this inducible population, constitutive erm-expressing mutants exist at low frequency; under clindamycin therapy in vivo, clindamycin itself can act as a partial inducer and the constitutive mutants — which are always clindamycin-resistant regardless of inducer presence — have a strong selective advantage and can expand to cause clinical treatment failure despite an initial susceptible MIC. Clinical microbiology standards require reporting such isolates as clindamycin-resistant regardless of the MIC value. For this patient's wound infection, an alternative agent with demonstrated in vitro susceptibility — such as trimethoprim-sulfamethoxazole, doxycycline, or linezolid depending on full susceptibility results and clinical context — should be used.
Option B: Option B is incorrect because the D-zone test does not indicate a correction to an artifactually wide inhibition zone; it indicates inducible resistance that predicts clinical failure with clindamycin, and proceeding with clindamycin therapy on the basis of the susceptible MIC alone when a positive D-zone is present is the clinical error the test is designed to prevent.
Option C: Option C is incorrect because constitutive MLSB resistance produces complete, symmetric blunting of the clindamycin inhibition zone — not a D-shape — and the clindamycin MIC would not read susceptible with constitutive resistance; this is specifically an inducible pattern, and the MIC is not a laboratory error.
Option D: Option D is incorrect because the positive D-zone test indicates inducible erm methylase, not mef efflux pump overexpression; the M phenotype (mef-mediated) produces a negative D-zone test, and mef does not transport clindamycin under any conditions — the described transient induction of mef clindamycin efflux is pharmacologically incorrect.
Option E: Option E is incorrect because there is no validated category of D-zone false positives related to high-level erythromycin resistance MIC values; the D-zone test methodology specifically detects inducible erm expression, and a positive result in the appropriate disk geometry setting indicates inducible MLSB resistance regardless of the erythromycin MIC level.
5. A 67-year-old man with COPD and atrial fibrillation managed with warfarin (INR target 2.0 to 3.0, current INR 2.4) develops an acute exacerbation of COPD with features of atypical bacterial pneumonia. His physician wants to add a macrolide for atypical organism coverage. Which macrolide choice best minimizes anticoagulation risk, and what is the pharmacological basis for this recommendation?
A) Erythromycin is preferred because it is eliminated entirely by biliary excretion without hepatic CYP metabolism, making it pharmacokinetically inert with respect to warfarin; its lack of CYP involvement means no warfarin interaction occurs regardless of dose or duration of co-administration
B) Clarithromycin is preferred because its 14-hydroxyclarithromycin metabolite competitively inhibits the CYP2C9-mediated metabolism of the less potent R-warfarin enantiomer while leaving S-warfarin metabolism unaffected; this selective inhibition produces a modest, predictable INR increase of approximately 0.3 units that can be anticipated and managed without dose adjustment
C) Azithromycin is preferred because it produces negligible CYP3A4 inhibition and clinically insignificant CYP2C9 inhibition, minimizing its effect on warfarin plasma concentrations; erythromycin and clarithromycin inhibit CYP3A4 and can also inhibit CYP2C9 — which metabolizes the more potent S-warfarin enantiomer — potentially producing supratherapeutic anticoagulation and bleeding risk
D) All three macrolides carry equivalent warfarin interaction risk because the primary mechanism of macrolide-warfarin interaction is suppression of gut flora that produce vitamin K; since all three macrolides have equivalent antibacterial activity against gut flora, the INR elevation produced is the same regardless of macrolide choice, and INR should be rechecked in 5 to 7 days after any macrolide is started
E) Erythromycin is preferred over clarithromycin and azithromycin for patients on warfarin because erythromycin is a potent CYP2C9 inducer at the doses used for respiratory infections; CYP2C9 induction accelerates S-warfarin metabolism, reducing anticoagulant effect and protecting against supratherapeutic INR elevation during the antibiotic course
ANSWER: C
Rationale:
Warfarin's anticoagulant effect depends primarily on the pharmacologically more potent S-enantiomer, which is metabolized predominantly by CYP2C9. The less potent R-enantiomer is metabolized partly by CYP3A4. Erythromycin and clarithromycin can inhibit both CYP3A4 (primary mechanism, through the nitrosoalkane mechanism-based inhibition) and CYP2C9 (particularly clarithromycin), reducing warfarin clearance and elevating plasma concentrations of both enantiomers. The net effect is a rise in INR that can produce supratherapeutic anticoagulation and bleeding risk. Additionally, any antibiotic that alters intestinal flora can reduce vitamin K production by gut bacteria, contributing a secondary mechanism to INR elevation. Azithromycin produces negligible CYP3A4 inhibition (does not generate the nitrosoalkane CYP3A4 inhibitory intermediate) and clinically insignificant CYP2C9 inhibition, making it the preferred macrolide in patients on warfarin. While any antibiotic can affect gut flora and secondarily influence vitamin K levels, the direct CYP inhibitory interaction that produces the most clinically significant INR changes is avoided with azithromycin. INR monitoring during any macrolide course in anticoagulated patients is prudent, but the pharmacokinetic risk is substantially lower with azithromycin.
Option A: Option A is incorrect because erythromycin does undergo extensive hepatic CYP3A4 metabolism and is a potent CYP3A4 inhibitor; it is not pharmacokinetically inert with respect to warfarin — both direct CYP interaction and gut flora effects contribute to INR elevation with erythromycin.
Option B: Option B is incorrect because clarithromycin does not selectively inhibit R-warfarin metabolism while sparing S-warfarin; clarithromycin inhibits both CYP3A4 and CYP2C9 and can affect both enantiomers, and a predictable 0.3 INR unit increase as described is an oversimplification that understates the interaction risk.
Option D: Option D is incorrect because macrolides are not equivalent in their warfarin interaction risk; the CYP-mediated interactions of erythromycin and clarithromycin are pharmacokinetically distinct from azithromycin's negligible CYP inhibition, and the gut flora suppression component alone does not account for the clinically significant INR elevations seen with erythromycin and clarithromycin.
Option E: Option E is incorrect because erythromycin is a CYP3A4 and CYP2C9 inhibitor, not an inducer; CYP enzyme inducers include rifampin, carbamazepine, and phenytoin — not macrolides — and the clinical consequence of erythromycin on warfarin is INR elevation from reduced warfarin clearance, not the protective INR reduction described.
6. A 34-year-old woman is prescribed oral erythromycin ethylsuccinate for a community-acquired skin and soft tissue infection. Two days into therapy she calls the office reporting severe nausea, vomiting, and abdominal cramping that begin within 30 minutes of each dose and are making the medication nearly impossible to tolerate. She has no fever and her wound appearance is improving. Which of the following best explains the mechanism responsible for her symptoms and identifies the most appropriate management?
A) Her symptoms represent erythromycin-induced cholestatic hepatitis; onset within 30 minutes of dosing is the characteristic rapid hypersensitivity pattern for the estolate ester formulation, and the gastrointestinal symptoms reflect hepatic inflammatory mediator release; erythromycin should be stopped immediately and liver function tests obtained before substituting an alternative antibiotic
B) Her symptoms represent a type I IgE-mediated hypersensitivity reaction to the ethylsuccinate ester moiety of erythromycin; the rapid onset after each dose is consistent with mast cell degranulation triggered by IgE-ester complex formation; erythromycin should be stopped and the patient evaluated for macrolide allergy before any macrolide is re-prescribed
C) Her symptoms represent direct gastric mucosal irritation from erythromycin's high concentration in the gastric lumen immediately after an oral dose; the ethylsuccinate formulation has the highest mucosal irritancy of all erythromycin formulations because it dissolves rapidly in the stomach rather than the small intestine; switching to the enteric-coated erythromycin stearate formulation would eliminate the symptoms by delaying dissolution past the stomach
D) Her symptoms represent the predictable pharmacological consequence of erythromycin's potent motilin receptor agonism in the gastrointestinal tract; erythromycin activates motilin receptors on gastric and intestinal smooth muscle, accelerating gastric emptying and increasing peristalsis in a dose-dependent, receptor-mediated manner unrelated to the drug's antibacterial properties; switching to azithromycin — which has substantially lower motilin receptor affinity — for the remainder of the course is appropriate given that the infection is responding
E) Her symptoms represent erythromycin-induced small bowel bacterial overgrowth caused by rapid GI transit that prevents normal intestinal flora establishment; the accelerated transit selectively eliminates anaerobic flora, allowing aerobic overgrowth that produces excess short-chain fatty acids and osmotic diarrhea; a probiotic containing Lactobacillus species taken simultaneously with each erythromycin dose would restore normal transit and eliminate symptoms
ANSWER: D
Rationale:
This presentation is the classic and predictable gastrointestinal intolerance pattern of erythromycin therapy. Erythromycin is a potent agonist at motilin receptors in the gastrointestinal tract. Motilin is an enteric peptide hormone that normally triggers the migrating motor complex during the interdigestive fasting period, stimulating gastric and small bowel contractions. Erythromycin's structural similarity to motilin allows it to activate these receptors at therapeutic doses, accelerating gastric emptying and increasing intestinal peristalsis — producing nausea, vomiting, and abdominal cramping that characteristically begin shortly after oral administration when gastric drug concentrations are highest. This mechanism is purely pharmacological and dose-dependent, unrelated to hypersensitivity, hepatotoxicity, or mucosal injury. Since the infection is responding clinically, switching to azithromycin for the remainder of the course is appropriate: azithromycin has substantially lower motilin receptor affinity than erythromycin, producing the best gastrointestinal tolerability profile among the three major macrolides, with equivalent atypical and gram-positive coverage for this indication.
Option A: Option A is incorrect because erythromycin estolate-associated cholestatic hepatitis has a characteristic onset of 10 to 20 days after starting therapy — not within 30 minutes of dosing — and presents with jaundice, right upper quadrant pain, and eosinophilia rather than acute nausea after each dose; furthermore, this patient is taking ethylsuccinate, not the estolate formulation.
Option B: Option B is incorrect because the described symptoms — nausea, vomiting, and cramping occurring predictably within 30 minutes of each dose in a pharmacologically consistent pattern — are characteristic of motilin receptor agonism, not IgE-mediated hypersensitivity, which would present with urticaria, angioedema, or anaphylaxis rather than isolated GI motility symptoms.
Option C: Option C is incorrect because the ethylsuccinate formulation is not characterized by higher mucosal irritancy than other formulations; erythromycin's GI adverse effects are receptor-mediated through motilin agonism, not due to direct mucosal irritation from concentrated drug in the gastric lumen, and switching formulations would not eliminate motilin receptor-mediated motility effects.
Option E: Option E is incorrect because erythromycin does not cause small bowel bacterial overgrowth through a mechanism of selective anaerobic flora elimination; its GI effects are direct receptor-mediated motility stimulation, and probiotics do not antagonize motilin receptor agonism.
7. A 26-year-old woman at 14 weeks gestation presents to her obstetrician. A routine cervical swab returns positive for Chlamydia trachomatis by nucleic acid amplification test (NAAT). She has no known drug allergies. Which of the following represents the most appropriate treatment regimen, and what is the pharmacological rationale for this choice over the current preferred regimen for non-pregnant adults?
A) Doxycycline 100 mg orally twice daily for 7 days is the preferred regimen in pregnancy because azithromycin crosses the placenta and achieves fetal tissue concentrations sufficient to disrupt fetal ribosomal protein synthesis during organogenesis; doxycycline does not cross the placenta due to its high protein binding and is therefore fetal-safe throughout pregnancy
B) Azithromycin 1 gram orally as a single dose is the preferred regimen for chlamydia in pregnancy; doxycycline — the currently preferred regimen for non-pregnant adults — is contraindicated throughout pregnancy because tetracyclines are incorporated into developing fetal calcified tissues including bone and teeth during the second and third trimesters, causing permanent discoloration and potential enamel hypoplasia
C) Amoxicillin 500 mg orally three times daily for 7 days is the preferred regimen for chlamydia in pregnancy; both azithromycin and doxycycline are contraindicated in pregnancy — azithromycin because its QTc-prolonging effect is amplified in the fetal cardiac conduction system, and doxycycline because of fetal bone and tooth effects — making amoxicillin the only safe first-line option
D) Levofloxacin 500 mg orally once daily for 7 days is the preferred regimen for chlamydia in pregnancy; fluoroquinolones are safe in the second trimester because fetal cartilage ossification is complete by 12 weeks, eliminating the risk of fluoroquinolone-associated fetal cartilage damage that applies only in the first trimester
E) Azithromycin 1 gram orally as a single dose followed by 500 mg daily for 4 days is the preferred regimen for chlamydia in pregnancy because single-dose azithromycin provides insufficient tissue concentrations in the gravid uterus; extended-course azithromycin is required because placental P-glycoprotein actively effluxes azithromycin from the fetoplacental unit, necessitating higher cumulative maternal doses to achieve adequate endocervical concentrations
ANSWER: B
Rationale:
Chlamydia trachomatis infection during pregnancy requires treatment to prevent adverse obstetric outcomes including preterm labor, premature rupture of membranes, and perinatal transmission to the neonate. Although doxycycline 100 mg twice daily for 7 days is now the preferred regimen for uncomplicated urogenital chlamydia in non-pregnant adults per updated CDC guidelines, doxycycline is contraindicated throughout pregnancy. Tetracyclines — including doxycycline — bind to calcium in developing calcified tissues and are incorporated into fetal bone and teeth during periods of active calcification in the second and third trimesters, causing permanent yellow-brown discoloration of primary dentition and potential enamel hypoplasia. Azithromycin 1 gram as a single oral dose remains the preferred treatment for chlamydia specifically in the pregnant patient, because this pharmacological class contraindication of tetracyclines in pregnancy makes doxycycline unacceptable. Azithromycin's single-dose regimen also supports adherence, which is clinically relevant in the outpatient obstetric setting.
Option A: Option A is incorrect because doxycycline is not fetal-safe due to high protein binding; tetracyclines do cross the placenta and are incorporated into fetal calcified tissues, producing the tooth and bone developmental effects that constitute the contraindication; this option inverts the correct pharmacological conclusion.
Option C: Option C is incorrect because azithromycin is not contraindicated in pregnancy and does not produce clinically significant fetal QTc prolongation at the standard 1-gram single dose; amoxicillin is not a current CDC-recommended first-line regimen for chlamydia in pregnancy, though it was used historically as an alternative.
Option D: Option D is incorrect because fluoroquinolones are not recommended for use in pregnancy throughout all trimesters due to concerns about fetal cartilage toxicity demonstrated in animal studies; fetal cartilage ossification is not complete by 12 weeks, and fluoroquinolones are generally avoided in pregnancy, not cleared after the first trimester.
Option E: Option E is incorrect because azithromycin 1 gram single dose is the established standard regimen for chlamydia in pregnancy with documented clinical efficacy; extended-course azithromycin is not required, and placental P-gp efflux of azithromycin is not the pharmacokinetic basis for an extended dosing regimen in pregnancy.
8. A 74-year-old man with gout and stage 3b chronic kidney disease (eGFR 32 mL/min/1.73m²) takes daily colchicine 0.6 mg for gout prophylaxis. His primary care physician prescribes clarithromycin for a community-acquired pneumonia without reviewing his medication list. Five days later the patient presents to the emergency department with profuse diarrhea, severe diffuse myalgia, and inability to walk. Laboratory results reveal white blood cell count 1.8 × 10⁹/L, platelet count 62 × 10⁹/L, CK 9,200 U/L, and creatinine 3.4 mg/dL (baseline 2.1 mg/dL). Which of the following best explains this presentation?
A) Clarithromycin caused direct bone marrow suppression through inhibition of mitochondrial protein synthesis in hematopoietic precursors by binding to mitochondrial 50S ribosomes; the renal failure developed from clarithromycin-induced tubular toxicity due to its high renal concentration in a patient with reduced glomerular filtration; colchicine played no role in this presentation
B) Clarithromycin and colchicine both prolong the QTc interval and their combination triggered repetitive ventricular arrhythmias that produced systemic hypoperfusion; multi-organ hypoperfusion caused ischemic myopathy, bone marrow suppression, and acute kidney injury; the patient should be immediately evaluated with an ECG and cardioverted if a rhythm abnormality is identified
C) Colchicine accumulated to toxic levels because clarithromycin inhibited renal tubular secretion of colchicine via OCT2 transporter blockade; the reduced eGFR of 32 mL/min prevented adequate compensatory renal filtration of colchicine, producing a sustained supratherapeutic colchicine concentration that caused the observed multisystem toxicity
D) This presentation represents clarithromycin-induced DRESS syndrome (drug reaction with eosinophilia and systemic symptoms); the bone marrow suppression, myopathy, and renal injury reflect macrolide-mediated T-cell activation against hematopoietic, muscular, and renal tissues; colchicine is not involved in this presentation and should be continued to prevent a gout flare during the acute illness
E) Clarithromycin simultaneously inhibited both CYP3A4-mediated hepatic metabolism and P-glycoprotein-mediated intestinal efflux of colchicine, substantially increasing colchicine bioavailability and reducing its clearance; the patient's CKD had already reduced his renal clearance of colchicine at baseline, leaving him with critically limited total clearance capacity; the resulting colchicine toxicity syndrome — GI toxicity, bone marrow suppression, myopathy, and acute kidney injury — is the direct pharmacological consequence of this triple clearance impairment
ANSWER: E
Rationale:
This is a presentation of colchicine toxicity precipitated by the pharmacokinetic drug interaction between colchicine and clarithromycin, amplified by pre-existing renal impairment. Colchicine's systemic exposure is limited under normal circumstances by two major pharmacokinetic mechanisms: CYP3A4-mediated hepatic metabolism, which reduces the fraction reaching systemic circulation after absorption, and P-glycoprotein (P-gp)-mediated efflux in the intestinal wall, which limits oral absorption by transporting drug back into the gut lumen. Clarithromycin is a potent inhibitor of both pathways simultaneously. When both CYP3A4 and P-gp are inhibited, more colchicine is absorbed per dose (reduced P-gp efflux) while less is cleared after absorption (reduced CYP3A4 metabolism) — a multiplicative pharmacokinetic interaction that can triple or quadruple colchicine exposure. In this patient, stage 3b CKD (eGFR 32) had already reduced the renal clearance of colchicine — a third elimination route — leaving him with a critically narrowed safety margin before the clarithromycin interaction was added. The resulting colchicine toxicity syndrome is characteristic and multi-systemic: profuse GI toxicity (colchicine disrupts intestinal epithelial cell division via microtubule disruption), bone marrow suppression (leukopenia, thrombocytopenia from impaired hematopoietic cell division), myopathy with rhabdomyolysis (microtubule disruption in skeletal muscle), and acute kidney injury from myoglobin and direct tubular effects. The FDA label for colchicine contraindicates its combined use with clarithromycin or erythromycin in patients with renal or hepatic impairment.
Option A: Option A is incorrect because clarithromycin does not cause direct bone marrow suppression through mitochondrial ribosome binding at therapeutic doses, and this presentation is explained entirely by colchicine toxicity from the drug interaction; the multisystem pattern — GI toxicity, cytopenias, myopathy, renal injury — is colchicine's signature toxicity syndrome.
Option B: Option B is incorrect because QTc prolongation from macrolide-colchicine interaction producing arrhythmia-mediated multi-organ hypoperfusion is not the mechanism; colchicine does not meaningfully prolong the QTc, and the presentation described is the well-characterized cellular toxicity of colchicine affecting dividing cells, not ischemic organ damage from arrhythmia.
Option C: Option C is incorrect because OCT2 transporter inhibition causing reduced renal tubular secretion of colchicine is not the primary mechanism of the clarithromycin-colchicine interaction; the dominant pathways are CYP3A4 and P-gp inhibition affecting hepatic metabolism and intestinal absorption, not renal tubular secretion.
Option D: Option D is incorrect because this presentation is not DRESS syndrome — DRESS typically features extensive maculopapular rash, lymphadenopathy, and has a different multi-organ involvement pattern; the presentation described here is the specific and well-established colchicine toxicity syndrome, and stopping colchicine is essential management.
9. A 22-year-old previously healthy college student presents with 6 days of gradually worsening dry cough, low-grade fever, headache, and malaise. Chest X-ray shows a diffuse bilateral interstitial infiltrate disproportionately mild compared to his symptoms. He was started on amoxicillin 500 mg three times daily 4 days ago by an urgent care provider with no improvement. He has no significant medical history and takes no other medications. Which of the following best explains why amoxicillin has been ineffective and identifies the most appropriate antibiotic change?
A) Amoxicillin is ineffective because the clinical and radiographic presentation is consistent with atypical pneumonia caused by obligate or facultative intracellular organisms — most likely Mycoplasma pneumoniae or Chlamydophila pneumoniae — which lack a peptidoglycan cell wall and are therefore intrinsically resistant to all beta-lactam antibiotics; switching to azithromycin or clarithromycin, which inhibit intracellular protein synthesis at the 50S ribosomal subunit, provides appropriate coverage for these organisms
B) Amoxicillin is ineffective because this patient has drug-resistant Streptococcus pneumoniae (DRSP) expressing altered penicillin-binding proteins (PBPs); a respiratory fluoroquinolone such as levofloxacin should be initiated immediately, as macrolides are also ineffective against DRSP and would not represent an appropriate alternative in a college-age patient with community exposure risk
C) Amoxicillin is ineffective because the bilateral interstitial pattern indicates viral pneumonia, most likely influenza or COVID-19, for which antibiotics of any class provide no benefit; the appropriate management is to stop amoxicillin, initiate oseltamivir empirically for influenza coverage, and add azithromycin only if bacterial superinfection develops as evidenced by consolidation on repeat imaging
D) Amoxicillin is ineffective because Legionella pneumophila, the most common cause of community-acquired pneumonia in young adults without comorbidities, produces a beta-lactamase that inactivates all aminopenicillins; switching to azithromycin is appropriate because azithromycin is the only antibiotic with activity against Legionella, which is intrinsically resistant to all other antibiotic classes including fluoroquinolones and tetracyclines
E) Amoxicillin is ineffective because this patient has Pneumocystis jirovecii pneumonia (PCP), which classically presents with an indolent course, bilateral interstitial infiltrates, and disproportionate hypoxia relative to symptoms; the appropriate treatment is trimethoprim-sulfamethoxazole, not azithromycin, and HIV testing should be performed given the PCP diagnosis
ANSWER: A
Rationale:
This presentation is classic atypical pneumonia — gradual onset, dry cough, low-grade fever, systemic symptoms disproportionate to chest exam findings, and bilateral interstitial infiltrate on X-ray in a young previously healthy patient. The most common causes in this demographic are Mycoplasma pneumoniae and Chlamydophila pneumoniae (formerly Chlamydia pneumoniae), both of which are intracellular or obligate intracellular organisms. The mechanistic reason amoxicillin is ineffective is fundamental: both organisms lack a conventional peptidoglycan cell wall. Beta-lactam antibiotics — including amoxicillin — act exclusively by binding to penicillin-binding proteins (PBPs) and inhibiting peptidoglycan cross-linking; organisms without peptidoglycan have no target for beta-lactam activity and are intrinsically resistant regardless of dose. Macrolides, by contrast, enter host cells and inhibit protein synthesis at the 50S ribosomal subunit of these organisms within the intracellular environment, providing effective treatment. Azithromycin or clarithromycin is the appropriate switch for outpatient atypical pneumonia in a young low-risk patient, with the caveat that in regions with rising macrolide-resistant M. pneumoniae, doxycycline or a fluoroquinolone is an alternative.
Option B: Option B is incorrect because DRSP resistance is mediated by altered PBPs in an organism that retains a cell wall, presenting differently from atypical pneumonia; DRSP would more likely produce lobar consolidation, not bilateral interstitial infiltrates, and macrolides do have activity against atypical organisms regardless of pneumococcal resistance patterns.
Option C: Option C is incorrect because while viral pneumonia can present with interstitial infiltrates, the 6-day course without improvement on amoxicillin combined with the classic atypical syndrome (gradual onset, dry cough, systemic symptoms, bilateral interstitial pattern) strongly suggests Mycoplasma or Chlamydophila rather than influenza; empiric antiviral therapy without microbiological support is not the appropriate first step, and azithromycin should be started for the likely bacterial atypical etiology.
Option D: Option D is incorrect because Legionella is not the most common cause of CAP in young adults without comorbidities — it is more common in older patients or those with immunosuppression or environmental exposures; Legionella has a cell wall but is intrinsically resistant to most beta-lactams through a combination of beta-lactamase production (in many strains) and inherently low penicillin-binding protein affinity — not through absence of a cell wall target; and azithromycin is not the only effective antibiotic for Legionella — fluoroquinolones and doxycycline are also active.
Option E: Option E is incorrect because PCP characteristically occurs in immunocompromised patients, particularly those with HIV and CD4 counts below 200 cells/μL, not in a previously healthy 22-year-old without immunosuppression risk factors; PCP is not in the differential for community-acquired bilateral interstitial pneumonia in an immunocompetent young adult.
10. A 69-year-old woman with chronic heart failure and persistent atrial fibrillation managed with amiodarone is admitted for community-acquired pneumonia requiring IV antibiotic therapy. Her ECG on admission shows a QTc interval of 470 milliseconds. The team decides to use a macrolide for atypical coverage alongside a beta-lactam. Which of the following best guides macrolide selection and monitoring in this patient?
A) Erythromycin is the preferred macrolide in this patient because its short half-life of 1.5 to 2 hours means that any QTc prolongation is brief and self-limited; QTc monitoring is not required because the effect fully reverses within 8 hours of each dose, preventing sustained arrhythmia risk
B) All three major macrolides are equally contraindicated in this patient because a baseline QTc exceeding 450 milliseconds in a woman is an absolute contraindication to all macrolide use regardless of clinical indication; a non-macrolide antibiotic with atypical coverage such as doxycycline should be substituted without further consideration of macrolide options
C) Azithromycin is preferred over erythromycin because azithromycin carries lower QTc prolongation potential among the macrolides, though it is not risk-free; the combination of azithromycin's IKr block with amiodarone's independent multi-mechanism QTc prolongation and the patient's already elevated baseline QTc creates compounded risk; QTc should be monitored after the first dose and electrolytes — particularly potassium and magnesium — maintained in the upper normal range throughout therapy
D) Clarithromycin is the safest macrolide choice because its CYP3A4 inhibition of amiodarone metabolism reduces amiodarone plasma concentrations, shortening the QTc interval toward normal and providing a pharmacokinetic counterbalance to clarithromycin's own modest QTc-prolonging effect; net QTc change with this combination is negligible
E) Macrolide use is absolutely contraindicated in any patient receiving amiodarone because amiodarone's irreversible covalent binding to hERG channels prevents any compensatory upregulation of IKr that would normally buffer macrolide-induced QTc prolongation; the combination invariably produces QTc intervals exceeding 600 milliseconds and ventricular fibrillation
ANSWER: C
Rationale:
This patient has multiple risk factors for macrolide-associated torsades de pointes (TdP): a baseline QTc of 470 ms (already prolonged — upper limit of normal is approximately 450 ms in women), concurrent amiodarone therapy (which independently prolongs the QTc through IKr block, IKs block, and sodium channel inhibition), heart failure (associated with ion channel remodeling that increases arrhythmia susceptibility), and female sex (an independent risk factor for drug-induced TdP). Despite these risks, pneumonia requiring atypical organism coverage represents a real clinical need, and macrolide therapy can be undertaken with appropriate agent selection and monitoring. Among the macrolides, azithromycin carries lower QTc prolongation potential than erythromycin in most assessments, though it is not without cardiac risk — the 2012 Ray et al. NEJM cohort study documented increased cardiovascular death rates with azithromycin compared to amoxicillin, concentrated in patients with pre-existing cardiovascular disease. Azithromycin is therefore preferred over erythromycin in this patient. Critically, the combination of azithromycin's IKr block with amiodarone's baseline QTc prolongation is additive, and the already-elevated QTc means there is reduced repolarization reserve before TdP threshold is reached. Active QTc monitoring after the first dose and maintenance of potassium and magnesium in the upper normal range — to maximize IKr channel activity and reduce independent hypokalemia-mediated QTc prolongation — are essential management elements.
Option A: Option A is incorrect because erythromycin's mechanism-based CYP3A4 inhibition means its drug interaction effects persist beyond its plasma half-life, and its QTc prolongation is not brief and self-limited; erythromycin carries higher QTc prolongation potential than azithromycin and is not preferred in this high-risk patient.
Option B: Option B is incorrect because a baseline QTc exceeding 450 ms in a woman is not an absolute contraindication to all macrolide therapy; it is a risk factor requiring careful agent selection, monitoring, and electrolyte management — a clinical judgment that must weigh the benefit of treating the pneumonia against the cardiac risk.
Option D: Option D is incorrect because clarithromycin's CYP3A4 inhibition of amiodarone would elevate, not reduce, amiodarone plasma concentrations — increasing rather than counterbalancing QTc prolongation; amiodarone is a CYP3A4 substrate and clarithromycin inhibits its metabolism, making this combination particularly hazardous.
Option E: Option E is incorrect because amiodarone does not bind covalently to hERG channels; it produces reversible IKr block among its multiple ion channel effects, and IKr channels do not lose all compensatory capacity in the presence of amiodarone; macrolide use is not invariably fatal with amiodarone, but does require careful management as described.
11. A 48-year-old woman was prescribed erythromycin estolate for a skin infection 16 days ago. She now presents with jaundice, right upper quadrant pain, fever, and pruritus. Laboratory results show alkaline phosphatase 480 U/L, total bilirubin 4.2 mg/dL, ALT 94 U/L, AST 88 U/L, and eosinophil count 890 cells/μL. Liver ultrasound shows no biliary ductal dilation. Which of the following correctly identifies this reaction, explains the feature that distinguishes it from a pattern seen more commonly in children, and states the appropriate implication for future macrolide prescribing?
A) This presentation represents erythromycin estolate-induced fulminant hepatic necrosis, a direct hepatotoxic reaction caused by a reactive quinone metabolite produced by CYP3A4 during high-dose erythromycin metabolism; the reaction is more common in children than adults because children express higher hepatic CYP3A4 activity, generating more toxic metabolite per kilogram; all macrolides should be permanently avoided
B) This presentation represents macrolide-induced autoimmune hepatitis in which erythromycin estolate's propionate ester acts as a hapten after covalent binding to hepatocyte membrane proteins; eosinophilia confirms immune sensitization; the pattern is more common in children because the pediatric immune system mounts more exuberant hapten responses; corticosteroid therapy is required and all macrolides are contraindicated in future
C) This presentation represents erythromycin estolate-induced cholestatic hepatitis with a hepatocellular component, consistent with a mixed drug-induced liver injury pattern; the reaction is more common in children than adults because pediatric bile salt transporters are more susceptible to erythromycin's motilin receptor-mediated cholestatic effect; azithromycin is contraindicated because it undergoes identical biliary metabolism to erythromycin
D) This presentation is consistent with erythromycin estolate-associated cholestatic hepatitis — a hypersensitivity reaction characterized by cholestatic liver enzyme elevation, fever, and eosinophilia, appearing 10 to 20 days after starting therapy and resolving after drug discontinuation; the reaction is paradoxically more common in adults than in children, an unusual feature for drug hypersensitivity; erythromycin estolate should be stopped immediately; azithromycin and clarithromycin do not carry equivalent risk for this specific reaction and can be used in future when a macrolide is clinically indicated
E) This presentation represents erythromycin estolate-induced hepatic steatosis caused by inhibition of mitochondrial fatty acid oxidation by the propionate ester moiety; eosinophilia is present because circulating free fatty acids activate eosinophil degranulation; the pattern is more common in adults because adult hepatocytes rely more heavily on mitochondrial beta-oxidation; azithromycin is also contraindicated because its azalide nitrogen inhibits the same mitochondrial beta-oxidation pathway
ANSWER: D
Rationale:
This presentation has the defining features of erythromycin estolate-associated cholestatic hepatitis: onset 10 to 20 days after starting therapy (consistent with the sensitization period for a hypersensitivity reaction), cholestatic enzyme pattern (markedly elevated alkaline phosphatase and bilirubin with only modest transaminase elevation), fever, eosinophilia, and absence of biliary ductal obstruction on ultrasound confirming intrahepatic rather than obstructive cholestasis. The reaction is a hypersensitivity response specifically associated with the propionate estolate ester formulation of erythromycin, thought to involve the ester moiety rather than the core macrolide structure. A clinically important and distinctive feature is that the reaction is more common in adults than in children — an unusual epidemiological pattern for drug hypersensitivity reactions, which typically occur at higher rates in children or show no age predilection. The pathophysiological reason for this adult predominance is not fully established. Management requires immediate discontinuation of erythromycin estolate; the reaction resolves with drug withdrawal. Because the reaction is attributable to the estolate ester formulation and not to the macrolide pharmacophore shared across the class, azithromycin and clarithromycin do not carry equivalent risk for this specific reaction and are appropriate alternatives when a macrolide is needed in future.
Option A: Option A is incorrect because erythromycin estolate hepatitis is a hypersensitivity reaction, not direct hepatotoxic necrosis from a reactive quinone metabolite; the pattern (cholestatic, not hepatocellular necrosis; eosinophilia present; onset 10–20 days) supports hypersensitivity, and the reaction is more common in adults than children — not the reverse.
Option B: Option B is incorrect because erythromycin estolate hepatitis is not classified as autoimmune hepatitis with corticosteroid-responsive T-cell sensitization; corticosteroids are not the treatment (discontinuation resolves the reaction), and all macrolides are not contraindicated following this formulation-specific reaction.
Option C: Option C is incorrect because erythromycin estolate hepatitis is predominantly cholestatic rather than mixed, its mechanism is hypersensitivity rather than motilin receptor-mediated cholestasis, the reaction is more common in adults not children, and azithromycin is not contraindicated.
Option E: Option E is incorrect because erythromycin estolate hepatitis is not caused by mitochondrial beta-oxidation inhibition; that mechanism produces microvesicular steatosis (characteristic of valproic acid and NRTI toxicity), not the cholestatic hypersensitivity pattern seen here, and azithromycin does not inhibit mitochondrial beta-oxidation.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.